Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics

Nature Communications

Volumn 6, Issue , 2015, Pages

  Tsai, Chia Feng ^a,b   Wang, Yi Ting ^a,b,c   Yen, Hsin Yung ^a,d   Tsou, Chih Chiang ^e   Ku, Wei Chi ^f   Lin, Pei Yi ^b   Chen, Hsuan Yu ^g   Nesvizhskii, Alexey I ^e   Ishihama, Yasushi ^h   Chen, Yu Ju ^a,b,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b INSTITUTE OF CHEMISTRY   (Taiwan)

^c ACADEMIA SINICA   (Taiwan)

^d GENOMICS RESEARCH CENTER   (Taiwan)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^g INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

^h KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 2; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOTOPE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN; PHOSPHOTRANSFERASE; PROTEOME; VASCULOTROPIN RECEPTOR;

CHEMICAL PROCESS; DRUG RESISTANCE; ENZYME ACTIVITY; ISOTOPIC ANALYSIS; PROTEIN; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNALING; STOICHIOMETRY;

ARTICLE; ENZYME MECHANISM; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; LUNG CANCER; LUNG CANCER CELL LINE; MOLECULAR DYNAMICS; NON SMALL CELL LUNG CANCER; PROTEIN DEPHOSPHORYLATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TARGETING; PROTEOMICS; QUANTITATIVE ANALYSIS; QUANTITATIVE STUDY; REPRODUCIBILITY; SIGNAL TRANSDUCTION; STOICHIOMETRY; WORKFLOW; ALGORITHM; DRUG RESISTANCE; LIQUID CHROMATOGRAPHY; LUNG TUMOR; METABOLISM; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE; WESTERN BLOTTING;

ALGORITHMS; AMINO ACID MOTIFS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; PROTEOMICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY;

EID: 84925672689     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7622     Document Type: Article

References (36)

1. Daub, H. Kinase inhibitors: narrowing down the real targets. Nat. Chem. Biol. 6, 249-250 (2010).
2. Miinea, C. P. & Lienhard, G. E. Stoichiometry of site-specific protein phosphorylation estimated with phosphopeptide-specific antibodies. Biotechniques 34, 828-831 (2003).
3. Cooper, J. A. Estimation of phosphorylation stoichiometry by separation of phosphorylated isoforms. Methods Enzymol. 201, 251-261 (1991).
4. Sefton, B. M. Measurement of stoichiometry of protein phosphorylation by biosynthetic labeling. Methods Enzymol. 201, 245-251 (1991).
5. Wu, R. et al. Correct interpretation of comprehensive phosphorylation dynamics requires normalization by protein expression changes. Mol. Cell Proteomics 10, 009654 (2011).
6. Olsen, J. V. et al. Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci. Signal. 3, ra3 (2010).
7. Wu, R. et al. A large-scale method to measure absolute protein phosphorylation stoichiometries. Nat. Methods 8, 677-683 (2011).
8. Schwartz, D. & Gygi, S. P. An iterative statistical approach to the identification of protein phosphorylation motifs from large-scale data sets. Nat. Biotechnol. 23, 1391-1398 (2005).
9. Pflieger, D. et al. Quantitative proteomic analysis of protein complexes: concurrent identification of interactors and their state of phosphorylation. Mol. Cell Proteomics 7, 326-346 (2008).
10. Kosaka, T., Yamaki, E., Mogi, A. & Kuwano, H. Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J. Biomed. Biotechnol. 2011, 165214 (2011).
11. Yatabe, Y. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev. 29, 23-36 (2010).
12. Engelman, J. A. & Janne, P. A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 14, 2895-2899 (2008).
13. Huang, M. H. et al. MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. Mol. Oncol. 7, 112-120 (2013).
14. Keshava Prasad, T. S. et al. Human protein reference database - 2009 update. Nucleic Acids Res. 37, D767-D772 (2009).
15. Dinkel, H. et al. Phospho.ELM: a database of phosphorylation sites-update 2011. Nucleic Acids Res. 39, D261-D267 (2011).
16. Hornbeck, P. V. et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res. 40, D261-D270 (2012).
17. Magrane, M. & Consortium, U. UniProt Knowledgebase: a hub of integrated protein data. Database (Oxford) 2011, bar009 (2011).
18. Li, H. et al. SysPTM: a systematic resource for proteomic research on post-translational modifications. Mol. Cell Proteomics 8, 1839-1849 (2009).
19. Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007).
20. Russo, G. L. et al. Casein kinase II phosphorylates p34cdc2 kinase in G1 phase of the HeLa cell division cycle. J. Biol. Chem. 267, 20317-20325 (1992).
21. Bloom, J. & Cross, F. R. Multiple levels of cyclin specificity in cell-cycle control. Nat. Rev. Mol. Cell Biol. 8, 149-160 (2007).
22. Bouwman, P. & Jonkers, J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat. Rev. Cancer 12, 587-598 (2012).
23. Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714-726 (2013).
24. Flint, M. S. et al. Stress hormones mediate drug resistance to paclitaxel in human breast cancer cells through a CDK-1-dependent pathway. Psychoneuroendocrinology 34, 1533-1541 (2009).
25. Zhang, Y. et al. High-mobility group A1 proteins enhance the expression of the oncogenic miR-222 in lung cancer cells. Mol. Cell Biochem. 357, 363-371 (2011).
26. Liau, S. S. &Whang, E.HMGA1 is amolecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin. Cancer Res. 14, 1470-1477 (2008).
27. Imamura, H., Sugiyama, N., Wakabayashi, M. & Ishihama, Y. Large-scale identification of phosphorylation sites for profiling protein kinase selectivity. J. Proteome Res. 13, 3410-3419 (2014).
28. Rappsilber, J., Mann, M. & Ishihama, Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat. Protoc. 2, 1896-1906 (2007).
29. Boersema, P. J., Raijmakers, R., Lemeer, S., Mohammed, S. & Heck, A. J. Multiplex peptide stable isotope dimethyl labeling for quantitative proteomics. Nat. Protoc. 4, 484-494 (2009).
30. Tsai, C. F. et al. Immobilized metal affinity chromatography revisited: pH/acid control toward high selectivity in phosphoproteomics. J. Proteome Res. 7, 4058-4069 (2008).
31. Tsai, C. F. et al. Sequential phosphoproteomic enrichment through complementary metal-directed immobilized metal ion affinity chromatography. Anal. Chem. 86, 685-693 (2014).
32. Savitski, M. M. et al. Confident phosphorylation site localization using the Mascot Delta Score. Mol. Cell Proteomics 10, 003830 (2011).
33. Vizcaino, J. A. et al. The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res. 41, D1063-D1069 (2013).
34. Tsou, C. C. et al. DIA-Umpire: comprehensive computational framework for data-independent acquisition proteomics. Nat. Methods 12, 258-264 (2015).
35. Tsou, C. C. et al. IDEAL-Q, an automated tool for label-free quantitation analysis using an efficient peptide alignment approach and spectral data validation. Mol. Cell Proteomics 9, 131-144 (2010).
36. Franceschini, A. et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 41, D808-D815 (2013).